Axsome Therapeutics, Inc. (AXSM) · Aug 10, 2026 · Earnings

Strong product growth, but revenue and EPS trail published Q2 expectations

Strong product growth, but revenue and EPS trail published Q2 expectations

The quarter missed the market’s financial bar despite strong growth. Published expectations were roughly $225 million of revenue and a $0.86 per-share loss; Axsome delivered $218.4 million and a $0.99 loss, making this a modest revenue miss and a wider-than-expected loss.

MetricQ2 2026Q2 2025 / expectation
Total revenue$218.4M (Financial Highlights)$150.0M prior year; ~$225.1M published consensus
Net loss per share$(0.99) (Income Statement)$(0.97) prior year; about $(0.86) consensus
AUVELITY sales$180.3M (Financial Highlights)$119.6M prior year
SUNOSI revenue$35.8M (Financial Highlights)$30.0M prior year
SG&A expense$208.1M (Income Statement)$130.3M prior year
Cash and equivalents$319.9M (Balance Sheet)$322.9M at Dec. 31, 2025

AUVELITY remains the core positive, with early Alzheimer’s-agitation traction supporting the growth story. AUVELITY sales rose 51% year over year to $180.3 million, while total prescriptions increased 12% sequentially to approximately 266,000. New-to-brand prescriptions among patients aged 65 and older rose 126% during the first eight weeks after the June launch, although that is an early adoption indicator rather than established recurring demand (Commercial Highlights — AUVELITY).

The earnings miss was largely an investment decision, not a collapse in demand. SG&A jumped 60% year over year to $208.1 million because of sales-force expansion and the Alzheimer’s-agitation and SYMBRAVO launches, while R&D fell to $46.2 million. That spending helped produce strong revenue growth, but it also left the company with a $51.3 million quarterly loss and only roughly flat cash year to date (Income Statement; Balance Sheet). The company reaffirmed that current cash should fund operations into cash-flow positivity, but provided no numerical profitability timetable (Financial Guidance).

Pipeline progress adds support, but most of it is milestone value rather than near-term earnings. The FDA accepted AXS-12’s NDA with a May 1, 2027 target action date, pediatric ADHD Phase 3 trials began, and Axsome expects ENGAGE binge-eating-disorder topline data in the fourth quarter of 2026 (Development Pipeline; Anticipated Milestones). These are constructive execution updates, but they do not offset the immediate financial miss; the net read is mixed, with commercial momentum intact but quarterly results below expectations.

Original filing on SEC EDGAR

More Axsome Therapeutics, Inc. news

Strong product growth, but revenue and EPS trail published Q2 expectations | AXSM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.